Entera Presents Post-Hoc EB613 Phase 2 Findings at ASBMR 2026

Post-hoc Phase 2 data showed greater bone mineral density gains and anabolic effects with EB613 in postmenopausal women with osteoporosis than in women with osteopenia. Entera also showcased the Phase 3 design at the meeting.